Effects of short-term stanozolol administration on serum lipoproteins in hepatic lipase deficiency

Metabolism: Clinical and Experimental

Volumn 46, Issue 9, 1997, Pages 992-996

  Bausserman, Linda L ^a   Saritelli, Ann L ^b   Herbert, Peter N ^b  

^a MIRIAM HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; STANOZOLOL; TRIACYLGLYCEROL;

AGED; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; LIVER FUNCTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

EID: 0030819481     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90267-5     Document Type: Article

References (40)

1. Breckenridge WC, Little JA, Alaupovic P, et al: Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis 5:161-179, 1982
2. Carlson LA, Holmquist L, Nilsson-Ehle P: Deficiency of hepatic lipase activity in post-heparin plasma in familial hyper-triglyceridemia. Acta Med Scand 219:435-447, 1986
3. Auwerx JH, Babirak SP, Hokanson JE, et al: Coexistence of abnormalities of hepatic lipase and lipoprotein lipase in a large family. Am J Hum Genet 46:470-477, 1990
4. Hegele RA, Vezina C, Moorjani S, et al: A hepatic lipase gene mutation associated with heritable lipolytic deficiency. J Clin Endocrinol Metab 199:730-732, 1991
5. Connelly PW, Maguire GF, Lee M, et al: Plasma lipoproteins in familial hepatic lipase deficiency. Arteriosclerosis 10:40-48, 1990
6. Auwerx JH, Marzetta CA, Hokanson JE, et al: Large buoyant LDL-like particles in hepatic lipase deficiency. Arteriosclerosis 9:319-325, 1989
7. Ehnholm D, Shaw E, Greten H, et al: Purification from human plasma of a heparin-released lipase with activity against triglyceride and phospholipid. J Biol Chem 250:6756-6761, 1975
8. Brasaemle DL, Cornely-Moss K, Bensadoun A: Hepatic lipase treatment of chylomicron remnants increases exposure of apolipoprotein E. J Lipid Res 34:455-465, 1993
9. Demant T, Carlson LA, Holmquist L, et al: Lipoprotein metabolism in hepatic lipase deficiency: Studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res 29:1603-1611, 1988
10. Rubenstein A, Gibson JC, Paterniti JR Jr, et al: Effect of heparin-induced lipolysis on the distribution of apolipoprotein E among lipoprotein classes. J Clin Invest 75:710-721, 1985
11. Kuusi T, Saarinen P, Nikkila EA: Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein in man. Atherosclerosis 36:589-593, 1980
12. 3 by hepatic lipase. J Clin Invest 74:2017-2023, 1984
13. Shafi S, Brady SE, Bensadoun A, et al: Role of hepatic lipase in the uptake and processing of chylomicron remnants in rat liver. J Lipid Res 35:709-720, 1994
14. Bamberger M, Lund-Katz S, Phillips MC, et al: Mechanism of the hepatic lipase induced accumulation of high-density lipoprotein cholesterol by cells in culture. Biochemistry 24:3693-3701, 1985
15. Applebaum-Bowden D, Haffner SM, Wahl PW, et al: Postheparin plasma triglyceride lipases. Relationships with very low density lipoprotein triglyceride and high density lipoprotein cholesterol. Arteriosclerosis 5:273-383, 1985
16. Schaefer EJ, Lamon-Fava S, Ordovas JM, et al: Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham offspring study. J Lipid Res 35:871-882, 1994
17. Tikkanen MJ, Nikkila EA: Regulation of hepatic lipase and serum lipoproteins by sex steroids. Am Heart J 113:562-567, 1987
18. Taggart HM, Applebaum-Bowden D, Haffner S, et al: Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis. Metabolism 31:1147-1152, 1982
19. Haffner SM, Kushwaha RS, Foster DM, et al: Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism 32:413-420, 1983
20. Kantor MA, Bianchini A, Bernier D, et al: Androgens reduce HDL2-cholesterol and increase hepatic triglyceride lipase activity. Med Sci Sports Med 17:462-465, 1985
21. Tikkanen MJ, Kuusi T, Nikkila EA, et al: Post-menopausal hormone replacement therapy: Effects of progestogens on serum lipids and lipoproteins. A review. Maturitas 9:7-17, 1986
22. Tikkanen MJ, Nikkila EA, Kuusi T, et al: High density lipoprotein-2 and hepatic lipase: Reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 54:1113-1117, 1982
23. Colvin PL Jr, Auerbach BJ, Case LD, et al: A dose-response relationship between sex hormone-induced change in hepatic triglyceride lipase and high-density lipoprotein cholesterol in postmenopausal women. Metabolism 40:1052-1056, 1991
24. Applebaum-Bowden D, McLean P, Steinmetz A, et al: Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women. J Lipid Res 30:1895-1906, 1989
25. Allain CC, Poon LS, Chan CSG: Enzymatic determination of total serum cholesterol. Clin Chem 20:470-475, 1974
26. Kohlmeier M: Direct enzymic measurement of glycerides in serum and in lipoprotein fractions. Clin Chem 32:63-66, 1986
27. Gidez LI, Miller GJ, Burstein M, et al: Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 23:1206-1223, 1982
28. Sady SP, Thompson PD, Cullinane EM, et al: Prolonged exercise augments plasma triglyceride clearance. JAMA 256:2552-2555, 1986
29. Zunic G, Jelic-Ivanovic Z, Spasic S, et al: Reference values for apolipoproteins A-I and B in healthy subjects, by age. Clin Chem 38:566-569, 1992
30. Carroll M, Sempos R, Briefel R, et al: Serum lipids of adults 20-74 years, United States, 1976-1980. Vital Health Stat 11 242:1-107, 1993
31. Hegele RA, Little JA, Vezina C, et al: Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb 13:720-728, 1993
32. Durstenfeld A, Ben-Zeev O, Reue K, et al: Molecular characterization of human hepatic lipase deficiency. Arterioscler Thromb 14:381-385, 1994
33. Zmuda JM, Fahrenbach MC, Younkin BT, et al: The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity. Metabolism 42:446-450, 1993
34. Schaefer EJ, Foster DM, Zech LA, et al: The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 57:262-267, 1983
35. Thompson PD, Cullinane EM, Sady SP, et al: Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 261:1165-1168, 1989
36. Albers JJ, Taggart HM, Applebaum-Bowden D: Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta 795:293-296, 1984
37. Li KM, Wilcken DEL, Dudman NPB: Effect of serum lipoprotein(a) on estimation of low-density lipoprotein cholesterol by the Friedewald formula. Clin Chem 40:571-573, 1984
38. Glueck CJ: Effects of oxandrolone on plasma triglycerides and postheparin lipolytic activity in patients with types III, IV, and V familial hyperlipoproteinemia. Metabolism 20:691-702, 1971
39. Hazzard WR, Kushwaha RS, Applebaum-Bowden D, et al: Chylomicron and very low-density lipoprotein apolipoprotein B metabolism: Mechanism of the response to stanozolol in a patient with severe hypertriglyceridemia. Metabolism 33:873-881, 1984
40. 2 cholesterol. Metabolism 36:949-952, 1987